NO325822B1 - Anvendelse av isobutylgaba og dets derivater og salter for fremstilling av preparater for behandling av smerte. - Google Patents
Anvendelse av isobutylgaba og dets derivater og salter for fremstilling av preparater for behandling av smerte. Download PDFInfo
- Publication number
- NO325822B1 NO325822B1 NO19990279A NO990279A NO325822B1 NO 325822 B1 NO325822 B1 NO 325822B1 NO 19990279 A NO19990279 A NO 19990279A NO 990279 A NO990279 A NO 990279A NO 325822 B1 NO325822 B1 NO 325822B1
- Authority
- NO
- Norway
- Prior art keywords
- pain
- treated
- use according
- paw
- hyperalgesia
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 46
- 230000036407 pain Effects 0.000 title claims description 42
- 150000003839 salts Chemical class 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims description 30
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 14
- 208000004550 Postoperative Pain Diseases 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000001387 Causalgia Diseases 0.000 claims description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 62
- 208000004454 Hyperalgesia Diseases 0.000 description 57
- 210000002683 foot Anatomy 0.000 description 41
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 35
- 208000035154 Hyperesthesia Diseases 0.000 description 30
- 229960002870 gabapentin Drugs 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 27
- 238000001356 surgical procedure Methods 0.000 description 25
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 19
- 206010053552 allodynia Diseases 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 229960005181 morphine Drugs 0.000 description 17
- 230000004044 response Effects 0.000 description 14
- 229920001525 carrageenan Polymers 0.000 description 13
- 235000010418 carrageenan Nutrition 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000012353 t test Methods 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 210000000548 hind-foot Anatomy 0.000 description 6
- 230000003447 ipsilateral effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 229920005439 Perspex® Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- -1 aliphatic nitro compounds Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010056028 auromycin Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MNBODUCODDEXEE-UHFFFAOYSA-N ethyl 4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C MNBODUCODDEXEE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- OBLVSONFNRLRIQ-UHFFFAOYSA-N lithium;ethyl acetate Chemical compound [Li+].CCOC([CH2-])=O OBLVSONFNRLRIQ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2233796P | 1996-07-24 | 1996-07-24 | |
| PCT/US1997/012390 WO1998003167A1 (en) | 1996-07-24 | 1997-07-16 | Isobutylgaba and its derivatives for the treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO990279L NO990279L (no) | 1999-01-22 |
| NO990279D0 NO990279D0 (no) | 1999-01-22 |
| NO325822B1 true NO325822B1 (no) | 2008-07-21 |
Family
ID=21809080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19990279A NO325822B1 (no) | 1996-07-24 | 1999-01-22 | Anvendelse av isobutylgaba og dets derivater og salter for fremstilling av preparater for behandling av smerte. |
| NO2008018C NO2008018I2 (no) | 1996-07-24 | 2008-12-04 | (3S)-3-(Aminometyl)-5-metylheksansyre (Pregabalin)eller et farmasøytisk akseptabelt salt derav |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2008018C NO2008018I2 (no) | 1996-07-24 | 2008-12-04 | (3S)-3-(Aminometyl)-5-metylheksansyre (Pregabalin)eller et farmasøytisk akseptabelt salt derav |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | USRE41920E1 (hr) |
| EP (1) | EP0934061B3 (hr) |
| JP (1) | JP3693258B2 (hr) |
| KR (1) | KR100491282B1 (hr) |
| CN (1) | CN1094757C (hr) |
| AT (1) | ATE241351T1 (hr) |
| AU (1) | AU714980B2 (hr) |
| BR (1) | BR9710536A (hr) |
| CA (1) | CA2255652C (hr) |
| CU (1) | CU22850A3 (hr) |
| DE (1) | DE69722426T3 (hr) |
| DK (1) | DK0934061T6 (hr) |
| ES (1) | ES2200184T7 (hr) |
| HK (1) | HK1021134A1 (hr) |
| HR (1) | HRP970387A2 (hr) |
| HU (2) | HU228426B1 (hr) |
| IL (1) | IL126999A (hr) |
| NO (2) | NO325822B1 (hr) |
| NZ (1) | NZ332762A (hr) |
| PL (1) | PL189872B1 (hr) |
| PT (1) | PT934061E (hr) |
| SI (1) | SI0934061T1 (hr) |
| WO (1) | WO1998003167A1 (hr) |
| ZA (1) | ZA976562B (hr) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| DK1011658T3 (da) * | 1997-09-08 | 2006-04-03 | Warner Lambert Co | Analgesiske præparater, der omfatter antiepileptiske forbindelser, og fremgangsmåder til anvendelse af samme |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| HU228771B1 (en) * | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| AU765246B2 (en) * | 1998-07-09 | 2003-09-11 | Warner-Lambert Company | Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles |
| KR20010074682A (ko) * | 1998-07-09 | 2001-08-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 부비동 두통을 완화시키기 위한 ｇａｂａ 유사체 및충혈제거제를 포함하는 조성물 |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| US20030045500A1 (en) * | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| ATE305778T1 (de) * | 1998-07-09 | 2005-10-15 | Warner Lambert Co | Behandlung von nierenkolik mit gaba-analogen |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| AU3735000A (en) * | 1999-05-05 | 2000-11-21 | Warner-Lambert Company | Modulation of substance p by gaba analogs and methods relating thereto |
| US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
| US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| DZ3253A1 (fr) * | 1999-06-10 | 2000-12-21 | Warner Lambert Co | Acides 3-propyle gamma-aminobutyriques monosubstitues et disubstitues |
| EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| IL152925A (en) * | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| EE05216B1 (et) * | 2000-01-27 | 2009-10-15 | Warner-Lambert Company | Pregabaliini asmmeetriline sntees |
| US6687187B2 (en) * | 2000-08-11 | 2004-02-03 | Phonak Ag | Method for directional location and locating system |
| CA2356829A1 (en) * | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| EP1243262B1 (en) * | 2001-03-20 | 2006-05-31 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
| PT1243263E (pt) * | 2001-03-21 | 2003-03-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| EP2085087A1 (en) * | 2001-06-11 | 2009-08-05 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| WO2002100344A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
| WO2003077902A1 (en) * | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| AU2003243180A1 (en) * | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| WO2004052360A1 (en) * | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| AU2003297909A1 (en) * | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
| WO2004054565A1 (en) * | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20090118994A (ko) | 2002-12-13 | 2009-11-18 | 워너-램버트 캄파니 엘엘씨 | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 |
| PL377286A1 (pl) * | 2002-12-13 | 2006-01-23 | Warner-Lambert Company Llc | Analogi gabapentyny do włókniako-mięśniakowych i innych pokrewnych zaburzeń |
| PL377520A1 (pl) * | 2002-12-13 | 2006-02-06 | Warner-Lambert Company Llc | Pochodne pregabaliny przeznaczone do leczenia fibromialgii i innych zaburzeń |
| US20080318908A1 (en) * | 2002-12-17 | 2008-12-25 | Trustees Of Tufts College | Use of gaba and gabab agonists |
| CA2537402C (en) | 2003-09-12 | 2009-05-05 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| KR101157436B1 (ko) * | 2003-09-17 | 2012-07-05 | 제노포트 인코포레이티드 | Ｇａｂａ 유사체의 전구약물을 이용한 하지불안 증후군의치료 또는 예방 |
| PL1677767T3 (pl) | 2003-10-14 | 2011-12-30 | Xenoport Inc | Krystaliczna postać analogu kwasu gamma-aminomasłowego |
| DE602004020657D1 (de) * | 2003-12-02 | 2009-05-28 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen |
| JP2007528893A (ja) * | 2004-03-12 | 2007-10-18 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｃ１対称ビスホスフィンリガンド及びプレガバリンの不斉合成におけるそれらの使用 |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| ES2309731T3 (es) * | 2004-04-01 | 2008-12-16 | Warner-Lambert Company Llc | Preparacion de fosfolanos p-quirogenicos y su uso en sintesis asimetrica. |
| CN1950101B (zh) | 2004-04-16 | 2011-03-30 | 舒沃茨药物股份公司 | 肽化合物用于预防和治疗慢性头痛的用途 |
| EP1604655A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| RS51210B (sr) * | 2004-06-21 | 2010-12-31 | Warner-Lambert Company Llc. | Dobijanje pregaballina i srodnih jedinjenja |
| NZ552651A (en) * | 2004-08-27 | 2010-07-30 | Sanol Arznei Schwarz Gmbh | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
| CN102429882B (zh) | 2004-11-04 | 2015-03-25 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
| MX2007000524A (es) * | 2005-05-10 | 2007-03-28 | Teva Pharma | Metodo para la preparacion de pregabalina y sales de ella. |
| ES2372700T3 (es) * | 2005-05-10 | 2012-01-25 | Teva Pharmaceutical Industries Ltd | Resolución óptica del ácido 3-carbamoilmetil-5-metil hexanoico. |
| WO2006124609A2 (en) * | 2005-05-16 | 2006-11-23 | Joseph Johnson | Methods and compositions for treating arg |
| EP1940380A2 (en) * | 2005-05-20 | 2008-07-09 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US7563923B2 (en) * | 2005-09-19 | 2009-07-21 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin |
| KR20080027880A (ko) * | 2006-05-24 | 2008-03-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | Ｒ-(+)-3-(카바모일메틸)-5-메틸헥산산 및 이의 염의 제조방법 |
| AU2007260207B2 (en) | 2006-06-15 | 2012-11-08 | Ucb Pharma Gmbh | Pharmaceutical composition with synergistic anticonvulsant effect |
| US8097754B2 (en) * | 2007-03-22 | 2012-01-17 | Teva Pharmaceutical Industries Ltd. | Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid |
| WO2009046309A2 (en) * | 2007-10-03 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof |
| EP2297090A1 (en) * | 2008-06-23 | 2011-03-23 | Teva Pharmaceutical Industries Ltd. | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| WO2010070593A2 (en) | 2008-12-19 | 2010-06-24 | Pfizer Ireland Pharmaceuticals | Malonate esters |
| WO2010099200A1 (en) | 2009-02-24 | 2010-09-02 | Nektar Therapeutics | Oligomer-amino acid conjugates |
| NZ596492A (en) | 2009-05-15 | 2013-08-30 | Redx Pharma Ltd | Redox drug derivatives |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| WO2011141923A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
| EP2575798B1 (en) | 2010-06-01 | 2017-08-09 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
| WO2012025861A1 (en) | 2010-08-23 | 2012-03-01 | Pfizer Manufacturing Ireland | Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin |
| US8466297B2 (en) | 2010-11-01 | 2013-06-18 | Milan Soukup | Manufacturing process for (S)-Pregabalin |
| WO2012059797A1 (en) | 2010-11-04 | 2012-05-10 | Lupin Limited | Process for synthesis of (s) - pregabalin |
| EP2809303A1 (en) | 2012-01-30 | 2014-12-10 | Ranbaxy Laboratories Limited | Pregabalin gr tablets |
| AU2013213769A1 (en) | 2012-01-30 | 2014-08-21 | Sun Pharmaceutical Industries Limited | Gastroretentive tablets |
| CN102966602B (zh) * | 2012-12-14 | 2015-08-05 | 江苏海鸥冷却塔股份有限公司 | 一种冷却塔节能导流风筒 |
| WO2014112152A1 (ja) | 2013-01-18 | 2014-07-24 | 有限会社ケムフィズ | 神経因性疾病の治療のための医薬 |
| MX2015013589A (es) | 2013-03-27 | 2016-06-23 | Pfizer Ireland Pharmaceuticals | Proceso e intermediario para la preparacion de pregabalina. |
| MA44212A (fr) | 2015-05-26 | 2018-12-26 | Isa Odidi | Prégabaline à libération prolongée contrôlée |
| GB201617380D0 (en) * | 2016-10-13 | 2016-11-30 | St George's Hospital Medical School | Treatment for Osteoarthritis |
| KR102039345B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 고팽윤성 서방성 삼중정제 |
| KR102039344B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 경구용 서방성 삼중정제 |
| GB201703123D0 (en) * | 2017-02-27 | 2017-04-12 | St George's Hospital Medical School | Biomarkers |
| EP4227293A3 (en) | 2018-05-14 | 2023-10-04 | Xgene Pharmaceutical Inc | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
| CN108926573A (zh) * | 2018-07-03 | 2018-12-04 | 泓博元生命科技（深圳）有限公司 | 一种可降低尿酸指数的nadh组合物及其制备方法及应用 |
| KR20200056719A (ko) | 2018-11-15 | 2020-05-25 | 단국대학교 천안캠퍼스 산학협력단 | 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물 |
| WO2021191108A1 (en) | 2020-03-23 | 2021-09-30 | Plus Vitech, S.L. | Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid |
| WO2022038131A1 (en) | 2020-08-19 | 2022-02-24 | Plus Vitech, S.L. | Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage |
| WO2022234110A1 (en) | 2021-05-07 | 2022-11-10 | Plus Vitech, S.L. | Gamma-aminobutyric acid derivatives for use in cancer therapy |
| WO2022243430A1 (en) | 2021-05-20 | 2022-11-24 | Plus Vitech, S.L. | Treatment of acne |
| WO2022253748A1 (en) | 2021-06-03 | 2022-12-08 | Plus Vitech, S.L. | Combinations for the treatment of hpv |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| JPS4940460Y2 (hr) | 1971-05-19 | 1974-11-06 | ||
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| US4123438A (en) | 1975-03-05 | 1978-10-31 | Stamicarbon, B.V. | Process for preparing 2-pyrrolidones |
| NZ194348A (en) | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| US4322440A (en) | 1980-06-25 | 1982-03-30 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
| US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| DK373383A (da) | 1982-08-20 | 1984-02-21 | Midit | Fremgangsmaade til fremstilling af omega-aminosyrederivater |
| US4479005A (en) | 1982-12-16 | 1984-10-23 | The Dow Chemical Company | Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids |
| DE133795T1 (de) | 1983-08-01 | 1985-09-12 | The Mclean Hospital Corp., Belmont, Mass. | Gaba-ester und gaba-analoge ester. |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| GB8425872D0 (en) | 1984-10-12 | 1984-11-21 | Ciba Geigy Ag | Chemical compounds |
| DK170473B1 (da) | 1985-06-20 | 1995-09-11 | Daiichi Seiyaku Co | S(-)-pyridobenzoxazinforbindelser |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| JP2535001B2 (ja) | 1987-01-13 | 1996-09-18 | ダイセル化学工業株式会社 | Ｎ−アルキル化アミノ酸エステルの製法 |
| JPH07116064B2 (ja) | 1987-07-21 | 1995-12-13 | 三菱化学株式会社 | 分離剤 |
| US4908210A (en) | 1988-10-28 | 1990-03-13 | Eastman Kodak Company | Lactylic salt tablet formulations and tablets |
| GB8911017D0 (en) | 1989-05-13 | 1989-06-28 | Ciba Geigy Ag | Substituted aminoalkylphosphinic acids |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| GB8921304D0 (en) | 1989-09-20 | 1989-11-08 | Wyeth John & Brother Ltd | New method of treatment and heterocyclic compounds used therein |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US5025035A (en) | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| WO1992014443A1 (en) | 1991-02-20 | 1992-09-03 | Warner-Lambert Company | Microsphere-in-oil emulsion |
| DK204791D0 (da) | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
| SK283281B6 (sk) * | 1992-05-20 | 2003-05-02 | Northwestern University | Deriváty gamaaminomaslovej kyseliny, spôsoby a medziprodukty na ich výrobu, ich použitie a farmaceutické prostriedky |
| GB9308430D0 (en) | 1993-04-23 | 1993-06-09 | Glaxo Group Ltd | Medicaments |
| US5492927A (en) | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| US5792796A (en) | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| HU0102040D0 (en) | 1994-07-27 | 2001-07-30 | Warner Lambert Co | Purified gabapentine binding protein |
| GB9420784D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
| US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| ATE279406T1 (de) | 1995-01-12 | 2004-10-15 | Glaxo Group Ltd | Piperidinderivate mit tachykinin-antagonistischer wirkung |
| AU697610B2 (en) | 1995-02-28 | 1998-10-15 | H. Lundbeck A/S | 4-aminotetrahydrobenzisoxazole or -isothiazole compounds |
| US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| US5616793A (en) | 1995-06-02 | 1997-04-01 | Warner-Lambert Company | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| US5637767A (en) | 1995-06-07 | 1997-06-10 | Warner-Lambert Company | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| EP0888325B1 (en) | 1996-02-07 | 2002-05-29 | Warner-Lambert Company | Novel cyclic amino acids as pharmaceutical agents |
| NZ331143A (en) | 1996-03-14 | 2001-06-29 | Warner Lambert Co | Substituted cyclic amino acids as pharmaceutical agents |
| AU731279B2 (en) | 1996-03-14 | 2001-03-29 | Warner-Lambert Company | Novel bridged cyclic amino acids as pharmaceutical agents |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| WO1997049393A1 (en) | 1996-06-26 | 1997-12-31 | Warner-Lambert Company | Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis |
| SE9603408D0 (sv) | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| HRP980342A2 (en) | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| AU9019198A (en) | 1997-08-19 | 1999-03-08 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
| US6127418A (en) | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
| WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| DK1011658T3 (da) | 1997-09-08 | 2006-04-03 | Warner Lambert Co | Analgesiske præparater, der omfatter antiepileptiske forbindelser, og fremgangsmåder til anvendelse af samme |
| SI1045839T1 (en) | 1997-12-16 | 2004-06-30 | Warner-Lambert Company Llc | Novel amines as pharmaceutical agents |
| HU228772B1 (en) | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same |
| HU228771B1 (en) | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| WO2000002562A1 (en) | 1998-07-09 | 2000-01-20 | Warner-Lambert Company | Compositions comprising gaba analogs and caffeine |
| US20030045500A1 (en) | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| KR20010071778A (ko) | 1998-07-09 | 2001-07-31 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 불면증의 치료를 위한 ｇａｂａ 유사체의 용도 |
| PT1121114E (pt) | 1998-10-16 | 2007-03-30 | Warner Lambert Co | Utilização de análogos gaba para a produção de um medicamento para o tratamento da mania e da doença bipolar |
| EP1161263A1 (en) | 1999-03-10 | 2001-12-12 | Warner-Lambert Company Llc | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| WO2000061234A1 (en) | 1999-04-09 | 2000-10-19 | Warner-Lambert Company | Combinations of gaba analogs and tricyclic compounds to treat depression |
| ES2185591T3 (es) | 1999-06-02 | 2003-05-01 | Warner Lambert Co | Amino hererociclos utiles como agentes farmaceuticos. |
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
| ES2255500T3 (es) | 1999-07-02 | 2006-07-01 | Warner-Lambert Company Llc | Combinacion simergica. gabapentina y pregabalina. |
| US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| AU7904500A (en) | 1999-09-16 | 2001-04-17 | Warner-Lambert Company | Method for the screening of alpha2delta-1 subunit binding ligands |
| AP2002002501A0 (en) | 1999-10-07 | 2002-06-30 | Warner Lambert Co | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. |
| EE05216B1 (et) | 2000-01-27 | 2009-10-15 | Warner-Lambert Company | Pregabaliini asmmeetriline sntees |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| WO2001088101A2 (en) | 2000-05-16 | 2001-11-22 | Warner-Lambert Company | CELL LINE FOR THE EXPRESSION OF AN α2δ2 CALCIUM CHANNEL SUBUNIT |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| CA2356829A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| HUP0302555A3 (en) | 2000-11-30 | 2005-06-28 | Pfizer Prod Inc | Pharmaceutical compositions containing gaba agonists and aldose reductase inhibitors |
| CA2430298A1 (en) | 2000-11-30 | 2002-06-06 | Banavara Lakshman Mylari | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| ES2236134T3 (es) | 2000-12-13 | 2005-07-16 | Warner-Lambert Company Llc | Ligandos bisfosfolanos p-quirales y sus complejos con metales de transicion. |
| US20040002543A1 (en) | 2001-02-16 | 2004-01-01 | Leslie Magnus | Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain |
| ES2240657T3 (es) | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| MXPA02001147A (es) | 2001-03-19 | 2004-04-21 | Warner Lambert Co | Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica. |
| EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| US7022678B2 (en) | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| DE60216823T2 (de) | 2001-03-30 | 2007-10-04 | Pfizer Products Inc., Groton | Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren. |
| MXPA03009532A (es) | 2001-04-19 | 2004-02-12 | Warner Lambert Co | Aminoacidos biciclicos o triciclicos condensados. |
| SK286227B6 (sk) | 2001-05-25 | 2008-05-06 | Warner-Lambert Company Llc | Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie |
| US20030045449A1 (en) | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| DE10203122A1 (de) | 2002-01-25 | 2003-07-31 | Gruenenthal Gmbh | Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren |
| AU2003201716B2 (en) | 2002-01-31 | 2008-04-17 | Warner-Lambert Company Llc | Alpha 2 delta ligands to treat tinnitus |
| US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| US20030225149A1 (en) | 2002-04-30 | 2003-12-04 | Blazecka Peter G. | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids |
| IL165593A0 (en) | 2002-06-27 | 2006-01-15 | Warner Lambert Co | Use of an alpha2delta ligand such as gabapentin orpregabalin for treating attention deficit hyperac tivity disorder |
| MXPA05000345A (es) | 2002-07-08 | 2005-03-31 | Pfizer Prod Inc | Moduladores del receptor de glucocorticoides. |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US20040092522A1 (en) | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US7071339B2 (en) | 2002-08-29 | 2006-07-04 | Warner Lambert Company Llc | Process for preparing functionalized γ-butyrolactones from mucohalic acid |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| AU2003280188A1 (en) | 2002-12-06 | 2004-06-30 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
| WO2004054565A1 (en) | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| AU2004237951A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines |
| EP1644360A1 (en) | 2003-06-05 | 2006-04-12 | Warner-Lambert Company LLC | 3-substituted indoles and derivatives thereof as therapeutic agents |
| WO2005002585A1 (en) | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| WO2005021539A1 (en) | 2003-09-03 | 2005-03-10 | Pfizer Japan, Inc. | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| CA2537402C (en) | 2003-09-12 | 2009-05-05 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| KR20060087560A (ko) | 2003-09-12 | 2006-08-02 | 워너-램버트 캄파니 엘엘씨 | 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물 |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| MXPA06003396A (es) | 2003-09-25 | 2006-06-08 | Warner Lambert Co | Profarmacos de aminoacidos con afinidad por la proteina a 2d. |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| EP1543831A1 (en) | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
| JP2007537151A (ja) | 2004-01-29 | 2007-12-20 | ファイザー・プロダクツ・インク | γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ |
| GB0405200D0 (en) | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
| JP2007528893A (ja) | 2004-03-12 | 2007-10-18 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｃ１対称ビスホスフィンリガンド及びプレガバリンの不斉合成におけるそれらの使用 |
| JP2007530656A (ja) | 2004-03-29 | 2007-11-01 | ファイザー株式会社 | ＯＲＬ１受容体拮抗薬としてのαアリールまたはヘテロアリールメチルβピペリジノプロパンアミド化合物 |
| ES2309731T3 (es) | 2004-04-01 | 2008-12-16 | Warner-Lambert Company Llc | Preparacion de fosfolanos p-quirogenicos y su uso en sintesis asimetrica. |
| DE602005011784D1 (de) | 2004-04-07 | 2009-01-29 | Pfizer | Pyrazoloä4,3-düpyrimidine |
| UA82292C2 (uk) | 2004-04-14 | 2008-03-25 | Пфайзер Продактс Инк. | Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти) |
| CA2563707A1 (en) | 2004-04-20 | 2005-11-03 | Pfizer Inc. | Method of treating neuropathic pain using a crth2 receptor antagonsit |
| BRPI0509993A (pt) | 2004-04-20 | 2007-10-16 | Pfizer Prod Inc | combinações compreendendo ligandos de alfa-2-delta |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| CA2564994A1 (en) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| EA200801608A1 (ru) | 2004-06-15 | 2008-10-30 | Пфайзер Инк. | Производные бензимидазолонкарбоновой кислоты |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| RS51210B (sr) | 2004-06-21 | 2010-12-31 | Warner-Lambert Company Llc. | Dobijanje pregaballina i srodnih jedinjenja |
| BRPI0512781A (pt) | 2004-06-29 | 2008-04-08 | Pfizer Prod Inc | método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila |
| US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| WO2006008640A1 (en) | 2004-07-15 | 2006-01-26 | Pharmacia & Upjohn Company Llc | Non-aqueous suspension containing a drug having an unpleasant taste |
| US7649004B2 (en) | 2004-07-23 | 2010-01-19 | Pfizer, Inc. | Pyridine derivatives |
| GB0419849D0 (en) | 2004-09-07 | 2004-10-13 | Pfizer Ltd | Pharmaceutical combination |
| ATE417830T1 (de) | 2004-11-02 | 2009-01-15 | Pfizer | Sulfonylbenzimidazolderivate |
| CN101087771A (zh) | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| KR20070094747A (ko) | 2004-11-29 | 2007-09-21 | 워너-램버트 캄파니 엘엘씨 | 치료용 피라졸로［３,４-ｂ］피리딘 및 인다졸 |
| NZ556627A (en) | 2005-02-22 | 2010-09-30 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| EP1858865B1 (en) | 2005-03-10 | 2009-09-16 | Pfizer Inc. | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds |
| AP2007004157A0 (en) | 2005-03-17 | 2007-10-31 | Pfizer | N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain |
| JP2008536910A (ja) | 2005-04-20 | 2008-09-11 | ファイザー・リミテッド | プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体 |
| BRPI0609879A2 (pt) | 2005-04-28 | 2010-05-11 | Pfizer Ltd | derivados de aminoácidos |
| EP1940380A2 (en) | 2005-05-20 | 2008-07-09 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands |
| WO2006129164A1 (en) | 2005-05-31 | 2006-12-07 | Pfizer Japan Inc. | Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| JP4234786B1 (ja) | 2005-11-08 | 2009-03-04 | ファイザー・リミテッド | ピラゾール誘導体およびその医学的使用 |
| EA200801145A1 (ru) | 2005-12-02 | 2008-10-30 | Пфайзер Лимитед | Спироциклические производные хиназолина в качестве ингибиторов pde7 |
| CA2530904C (en) | 2005-12-20 | 2013-10-08 | John Marino | Pharmaceutical agents for the treatment of pain associated with spinal cord injury |
| WO2007102058A1 (en) | 2006-03-06 | 2007-09-13 | Pfizer Products Inc. | Alpha-2-delta ligands for non-restorative sleep |
| GB0700786D0 (en) | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| BRPI0808634A2 (pt) | 2007-02-02 | 2014-08-05 | Pfizer Prod Inc | Compostos tricíclicos, composições e métodos. |
| WO2008132589A1 (en) | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
-
1997
- 1997-07-16 NZ NZ332762A patent/NZ332762A/xx not_active IP Right Cessation
- 1997-07-16 US US11/983,750 patent/USRE41920E1/en not_active Expired - Lifetime
- 1997-07-16 DE DE1997622426 patent/DE69722426T3/de not_active Expired - Lifetime
- 1997-07-16 PT PT97932617T patent/PT934061E/pt unknown
- 1997-07-16 ES ES97932617.0T patent/ES2200184T7/es active Active
- 1997-07-16 WO PCT/US1997/012390 patent/WO1998003167A1/en active IP Right Grant
- 1997-07-16 KR KR10-1999-7000577A patent/KR100491282B1/ko active IP Right Review Request
- 1997-07-16 CN CN97196041A patent/CN1094757C/zh not_active Expired - Lifetime
- 1997-07-16 JP JP50706298A patent/JP3693258B2/ja not_active Expired - Lifetime
- 1997-07-16 CA CA002255652A patent/CA2255652C/en not_active Expired - Lifetime
- 1997-07-16 AU AU36024/97A patent/AU714980B2/en not_active Expired
- 1997-07-16 US US09/043,358 patent/US6001876A/en not_active Expired - Lifetime
- 1997-07-16 HU HU9904361A patent/HU228426B1/hu active Protection Beyond IP Right Term
- 1997-07-16 IL IL12699997A patent/IL126999A/en not_active IP Right Cessation
- 1997-07-16 PL PL97331325A patent/PL189872B1/pl unknown
- 1997-07-16 DK DK97932617.0T patent/DK0934061T6/en active
- 1997-07-16 AT AT97932617T patent/ATE241351T1/de active
- 1997-07-16 SI SI9730545T patent/SI0934061T1/xx unknown
- 1997-07-16 EP EP97932617.0A patent/EP0934061B3/en not_active Expired - Lifetime
- 1997-07-16 BR BR9710536A patent/BR9710536A/pt not_active Application Discontinuation
- 1997-07-17 HR HR60/022,337A patent/HRP970387A2/hr not_active Application Discontinuation
- 1997-07-23 ZA ZA9706562A patent/ZA976562B/xx unknown
-
1999
- 1999-01-22 CU CU1999008A patent/CU22850A3/es unknown
- 1999-01-22 NO NO19990279A patent/NO325822B1/no not_active IP Right Cessation
- 1999-12-09 HK HK99105747A patent/HK1021134A1/xx not_active IP Right Cessation
-
2008
- 2008-12-04 NO NO2008018C patent/NO2008018I2/no unknown
-
2013
- 2013-08-27 HU HUS1300046C patent/HUS1300046I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO325822B1 (no) | Anvendelse av isobutylgaba og dets derivater og salter for fremstilling av preparater for behandling av smerte. | |
| Vergnes et al. | Opposite effects of GABAB receptor antagonists on absences and convulsive seizures | |
| CA2430470C (en) | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | |
| AU2002257680A1 (en) | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | |
| US20070082956A1 (en) | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. | |
| JP2018021023A (ja) | （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型 | |
| US20170143709A1 (en) | (s)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| WO1991006295A1 (en) | Analgesic composition containing optically pure s(+) flurbiprofen | |
| Walker et al. | Intrahippocampal administration of both the D-and the L-isomers of AP5 disrupt spontaneous alternation behavior and evoked potentials | |
| Bito et al. | Effects of Chronic Cholinesterase Inhibitor Treatment: I: The Pharmacological and Physiological Behavior of the Anti-ChE-Treated Monkey (Macaca mulatta) Iris | |
| KR102246748B1 (ko) | 디에틸 （２-시아노에틸）포스포네이트의 약학적 조성물 및 이의 용도 | |
| JP6457502B2 (ja) | ３−ベンジルスルホニルプロピオニトリルの医薬上の使用 | |
| JP2016533331A (ja) | ３，４−ビス−ベンジルスルホニルブタンニトリル及びその医薬上の使用 | |
| JP2016539179A (ja) | ４−メチルスルホニル−２−ブテンニトリル及びその医薬上の使用 | |
| Ates et al. | Effects of loreclezole on epileptic activity, EEG and behaviour in rats with absence seizures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: LYRICA - PREGABALIN; NAT. REG. NO/DATE: EU104279001-025 20060619; FIRST REG. NO/DATE: EU104279001-025 20040706 Spc suppl protection certif: 2008018 Filing date: 20081204 Extension date: 20190706 |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: WARNER LAMBERT COMPANY LLC, US |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Spc suppl protection certif: 2008018 |